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ABSTRACT. Recent developments in molecular biology, immunology, tissue culture, and embryo manipu-
lation have considerably enhanced man's ability to change living organisms. Potential benefits to mankind
have led to multi-billion dollar per year investments involving over 200 new companies and many existing
enterprises. Although various scientific problems involved in genetic engineering were insurmountable until
recently, many of these problems have now been at least partially solved. Concerns have shifted somewhat
toward issues involving: 1) the legality of patenting new life forms; 2) the question of the need for regulation;
3) safety; and 4) the public perception of science. The development of a high-tech industry around basic
biological science has left some researchers with divided interests and has, at the same time, led to useful
collaboration between industry and academe. Universities will soon face new tests of the basic premise of the
'universality' of knowledge gained from research as they attempt to patent and temporarily withhold publica-
tion of proprietary discoveries made with taxpayers' support.
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INTRODUCTION
Biotechnology was recently defined as "any technique
that uses living organisms (or parts of living organisms)
to make or modify products, or to improve plants or
animals, for beneficial use" (J. Wyngaarden; see National
Institutes of Health 1985). This broad definition covers
recombinant DNA techniques, monoclonal antibodies,
gene engineering of higher organisms, and so on. It can
also be loosely construed to include such traditional pro-
cesses as the production of antibiotics and food processing
by fermentation.
The fledgling biotechnology industry involves over
200 new companies and many established firms with
annual capital investments of billions of dollars (Blu-
menthal et al. 1986). By contrast, sales of recombinant
products for 1985 were estimated at $337 million (Em-
yanitoff and Weinert 1984). Thus, investment presently
exceeds income from sales, and investors hope to profit by
obtaining favorable patent and market positions.
The increasing ability of biologists to directly and
specifically manipulate genes in living organisms is
bringing about a revolution in the biological sciences. In
some respects, the biotechnological methods bring about
changes that are less dramatic than those produced by
traditional breeding and mutagenesis, since they may
involve one or a few specific gene functions instead of
selection for gross phenotypic changes involving many
genes. Nevertheless, the ability to produce specific
changes in somatic and germ tissues of living organisms
through genetic engineering has raised social and legal
questions that remain unresolved. Perhaps the most com-
pelling of these is the question of who controls living
matter and its derivatives. This issue involves not only
inventors' rights, but also the origin of the starting ma-
terial and its progeny, the legal regulation of living
"products" by the government, patentability of life
forms, legal liability, and environmental factors. For
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educators, other issues are involved. Among them are
assessment of future manpower needs, training pro-
grams, potential conflicts of interest, patent policy,
secrecy, animal rights, and consortium agreements in-
volving both the public and private sectors.
ECONOMICS OF BIOTECHNOLOGY
DEVELOPMENT
Much of the enabling knowledge of the present revolu-
tion in molecular biology has come about in the United
States as a result of federally sponsored research, particu-
larly research sponsored by the National Institutes of
Health (NIH). Projected expenditures for biotechnology
research during the coming year are shown in Figure 1.
By far the greatest source of government support is NIH.
It is appropriate that the principal beneficiary of this
research to date has been human medicine. In AIDS
(Acquired Immune Deficiency Syndrome) research alone,
the discovery of the agent, the determination of its total
structure, elucidation of the mode of transmission, diag-
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FIGURE 1. Estimated sources of funds for biotechnology research and
development in 1987. Data compiled from Blumenthal et al. (1986),
Wyngaarden (1985), and Shoemaker (1986). NIH, National Institute
of Health; NSF, National Science Foundation; EPA, Environmental
Protection Agency; USDA, U.S. Department of Agriculture.
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nosis of infection, and present vaccine development ef-
forts have all hinged on the use of the new molecular
genetics. Other examples of the benefits of molecular
biology in human medicine are too numerous to men-
tion. Altogether, federal commitments to biotechnology
development total about $2 billion. This large con-
tribution has given the United States the leading edge in
biotechnology development. In the private sector, new
corporations as well as established companies and limited
venture partnerships have also invested heavily. To date,
several billion dollars have been allocated to bio-
technology development, making these contributions a
prominant factor in the overall development of a new
industry. In addition, a recent study from the Center for
Health Policy and Management, Harvard University
(Blumenthal et al. 1986) suggested that the private in-
dustries are spending an additional $ 136 million annu-
ally to support biotechnology research in universities.
Despite the benefits, biotechnology (and other health
related) funding is small compared to other federal ex-
penditures. For example, the entire annual budget (ap-
prox. $5 billion) for all of NIH in 1986 was less than 2%
of the amount spent each year for defense. The proposed
space platform alone would cost more than three years of
budgeting for NIH. A comparison of NIH with other
federal research spending, reflecting relative national pri-
orities, is shown in Figure 2.
Sale of biotechnology products (e.g., recombinant hor-
mones, pharmaceuticals) is just beginning. Estimates
suggest that sales will increase exponentially for a num-
ber of years in that market (Emyanitoff and Weinert
1984). The need for materials such as recombinant bovine
growth hormone, which is used to increase milk produc-
tion in cows, will undoubtedly create lucrative and un-
foreseen markets for novel pharmaceutical products. For
example, Genentech Corporation plans to sell
$700 million per year of its recombinant plasminogen
activator (Nakaso 1987) by 1990. In agriculture, applica-
tions of genetic manipulation are potentially great, but
no comprehensive assessment of the overall impact can
yet be made, particularly since neither recombinant ani-
mals nor plants have been marketed.
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FIGURE 2. Disposition of estimated federal research budget for
1987. Data compiled from Smith (1986) and Shoemaker (1986).
DOD, Department of Defense. For names of other agencies, see
Figure 1.
The potential exists for genetic improvement in all
agricultural crops and animals. Attempts are being made
to use genetic engineering to develop resistance to pests
and pesticides, to change the nutritional value of food
proteins, to increase the size of meat animals, and to
insert nitrogen fixation genes into plants. It is likely that
all of our common food species will be altered eventually
by direct genetic manipulation. In addition, re-
combinant animal vaccines are being developed that
promise to provide resistance to diseases such as swine
pseudo-rabies. Specific examples and up-to-date informa-
tion on industrial research and development are reported
monthly in Genetic Engineering News (published by Mary
Ann Leibert, Inc., 1651 Third Ave., New York, NY
10128). Finally, it is even likely that "molecular farm-
ing" will enable produce animals such as cows and chick-
ens to secrete recombinant proteins in their milk and
eggs. Thus, a sector of the agricultural economy, which
is currently depressed and burdened with surplus, could
be used effectively to produce polymers, enzymes, nutri-
tional proteins, antibodies, vaccines, and hormones.
Steady improvements in the methods of recombinant
protein production should enable many industrial prod-
ucts to be made on an agricultural scale by the year 2000.
Ohio enterprises that have already contributed substan-
tial resources to biotechnology development include
Sohio (Cleveland), Monsanto (Columbus), Battelle
Memorial Institute (Columbus), Stolle Research and
Development Corporation (Cincinnati), Technology Un-
limited (Wooster), Enzyme Technology Corporation
(Ashland), Life Technologies (Chagrin Falls), and Em-
byrogen (Athens).
MANPOWER NEEDS
A recent issue of Science (18 July 1986) contained
118 job advertisements in all disciplines ranging from
administrators to laboratory technicians. Sixty-one
(>51%) of these involved some aspect of biotechnology
or molecular genetics. Data from the Bureau of Labor
Statistics indicate that by 1990 about 37,000 individuals
trained in areas underlying biotechnology will be needed
(R. Christophersson; see NIH 1985). One problem is
that training can take as long as 10 to 14 years (college,
doctoral, and post-doctoral training) for a Ph.D. Sub-
stantial lead time is therefore needed to train new people.
Industry can be expected to attract many of the more
promising individuals by offering higher salaries than
most universities can afford to pay. Thus, fewer scientists
with doctorates will remain in academe to train new
biotechnologists, creating a further shortage of trained
people. Obviously, a strong science and mathematics
background in high school will be essential if these can-
didates are to succeed. It should be recognized that many
of our present scientists were trained before the de-
emphasis of science and mathematics education and the
subsequent lowering of achievement test scores that
became apparent during the 1960s and 1970s. Thus, it
may be especially difficult to train students in the present
era. The education of a good scientist must begin in the
primary school.
The types of personnel needed in the biotechnology
industry are apt to be quite varied. Typically, a laboratory
consists of a principal investigator (Ph.D. or equivalent),
research associates, post-doctoral fellows, students, tech-
150 C. P. HODGSON Vol. 87
nicians, and support personnel. In addition, there will be
work for patent attorneys and people with MB As who are
knowledgeable in the biological sciences. Table I lists
some of the types of jobs presently available in university
and industrial laboratories, and a typical range of salaries.
Of those awarded the doctorate in biological science
in 1983, 67% were male; 86% were American; average
age at graduation was 30; and matriculation time
from B.A./B.S. to Ph.D. averaged 6.2 years. One-half
held Master's degrees as well as the doctorate; 67% went
on to post-doctoral studies. One-half worked in research
and development; 30% did some teaching (National Re-
search Council 1983). For a student interested in
biotechnology-related jobs, recommended courses of
study would include basic science (i.e., chemistry, phys-
ics, biological sciences) in high school and college,
mathematics through calculus, and appropriate graduate
training in the area of interest.
Training in biotechnology specialties is available
through several types of programs. For example, a num-
ber of short course topics are offered at Catholic Univer-
sity in Washington, DC, Michigan State University in
East Lansing, and at Cold Spring Harbor Laboratories in
New York. In Ohio, graduate level molecular biology
workshops are offered in the summer at The Ohio State
University's Agricultural Research and Development
Center in Wooster. Graduate programs in cell and mo-
lecular biology are available at The Ohio State University
in Columbus, at Ohio University in Athens, at Miami
University in Oxford, at the University of Cincinnati,
and at Case Western Reserve University in Cleveland. A
biotechnology program leading to a B.S. degree is offered
by the Rochester Institute of Technology in Rochester,
NY. Massachusetts Institute of Technology has been
awarded substantial funding from the National Science
Foundation to establish a biotechnology center, includ-
ing biotechnology training, and the University of Minne-
sota has an interdisciplinary Master's level program in
bioengineering. At this early time in the growth of the
industry, it would be difficult to speculate on the num-
ber, type, or quality of jobs that will be available in
future years. Technology development, government
TABLE 1
Salaries of biotechnology workers
Job title
Principal Investigator
Post-Doctoral Fellow
Research Associate
Pre-Doctoral Fellow
(Research Assistant,
Teaching Assistant)
Technician
Technician
Technician
Training required
Ph.D (or equivalent)
plus 2-5 years post-
doctoral training.
Ph.D. (or equivalent)
in appropriate bio-
technology discipline
Ph.D., or M.S. and
equivalent experience.
Bachelor's degree or
M.S. in appropriate
scientific discipline;
candidacy in graduate
program.
High School or Asso-
ciate degree
Bachelor's degree
Master's degree
Approximate
salary
(1986 dollars)
30,000-100,000
13,000- 40,000
13,000- 40,000
5,000- 15,000
9,000- 18,000
12,000- 30,000
15,000- 45,000
regulatory practices, and foreign competition will play a
major role in shaping the result.
FUTURE REGULATION OF BIOTECHNOLOGY
Until recently, most research in molecular genetics
was regulated by the Recombinant DNA Guidelines es-
tablished by NIH in the wake of the Asilomar Conference
on recombinant DNA safety in 1975. Over the years,
many of the safety concerns about recombinant DNA
research have been dealt with through careful study and
the development of simple biological containment fea-
tures in conjunction with "common sense" physical con-
tainment. The original NIH Guidelines for Recombinant
DNA Research have been simplified greatly, and many
recombinant experiments can now be conducted exempt
from regulation.
The essence of the present highly successful system is
a form of 'negative regulation.' First, the recombinant
guidelines are a voluntary set of restrictions that are
mandatory for federal grantee institutions, but that are
almost universally accepted by industry, academe, and a
number of foreign countries. Second, the guidelines do
not attempt to approve specific projects that fall under
broad, general headings; instead, they simply specify the
containment level necessary, if any. Potentially hazardous
experiments are kept at a higher level of biosafety, and are
subject to review by institutional biosafety committees,
by the Recombinant Advisory Committee (RAC), or by
the Director of NIH. Negative regulation frees RAC of
the necessity to approve most experiments.
More recently, experiments with viral gene vectors,
recombinant animals and plants, planned experiments in
human gene therapy, and others have raised questions
that the guidelines do not specifically address. Many
government regulatory agencies have subsequently
claimed jurisdiction. These include the Environmental
Protection Agency (EPA), the U.S. Department of Agri-
culture (USDA), the Food and Drug Administration
(FDA), the White House Office of Science and Tech-
nology Policy (OSTP), and NIH-RAC (OSTP 1986). It
remains to be seen if such a multi-agency consortium can
function effectively.
A major problem in regulation is the definition of bio-
technology itself and the conflicting regulatory paradigm
that biotechnology should be regulated no differently
than anything else. For example, in the new proposed
Federal Regulatory Guidelines from the Office of Science
and Technology Policy (1986), the FDA (p. 23309)
stated that regulation "must be based on the rational and
scientific evaluation of a product, and not on a priori
assumptions about certain processes." Later, the FDA
(p. 23309) reversed the argument stating that "new mar-
keting applications will be required for most products
manufactured using new biotechnology," even if they are
identical to other products. Thus, there is conflict within
the regulatory agencies concerning whether products or
processes are being regulated. Yet another concern in the
new regulatory guidelines is the concept of regulating
only "new" biotechnology. Apparently, the old products
(i.e., those associated with present jobs and markets) are
politically taboo. An example of this is found in the
proposed definition of pathogenic organisms. This defi-
nition includes all common animal gene expression vec-
tors (which are based on low-risk viruses), as well as
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guidelines-exempt, bacterial gene-cloning systems in-
volving gene vectors such as the bacterial viruses pBR-
322 and bacteriophage lambda. The exception is then
made (p. 23333) for those pathogens "used for labora-
tory research or commercial purposes and generally
recognized as nonpa thogen ic . " This appears to
"grandfather" the current vectors, while inhibiting the
development or use of the new generation of vectors that
are potentially better than those developed with pre-
vious technology.
There are probably several areas of legitimate regu-
latory concern. These include potential alteration of the
environment made by recombinant organisms, infec-
tivity of certain gene vector systems, and the production
of toxic, dangerous, or addicting substances by altered
organisms. It remains to be seen how the courts will
handle liability and perceived risk issues.
A possible impediment to biotechnology development
in the United States is the current litigious climate. The
concepts of a risk-free society and cradle-to-grave security
have created "glitches" in the legal system that allow a
single individual to halt important scientific projects.
For example, Rifkin (1983) has successfully used the
courts to stop genetic engineering projects by invoking
the need for environmental impact statements. Recently,
a highly promising vaccine against swine pseudo-rabies
was recalled because it involved a deletion of genetic
material from the virus. It is interesting that less precise
genetic alterations and deletions made with the old tech-
nology are acceptable for vaccine development, even
though they are not well understood. It is clear that
lawyers, judges, and the public will react out of fear and
ignorance if they do not understand the processes in-
volved. Daniel Koshland, Jr., Editor of Science, recently
commented (1985): "What concerns me is that some of
the fundamental concepts and methodologies of science
are outside the understanding of the vast majority of the
population, including its opinion makers . . . political
and civic decisions are frequently made . . . with no at-
tempt to obtain a control sample." In one instance, Con-
gressional leaders attempted to force the U.S. Patent
Office to grant a patent on a 'perpetual motion machine',
although the machine had failed tests performed by the
Patent Office. Dr. Koshland also observed that: "We
watch with consternation as society acts as if zero risk
could be achieved." It is true that the eternal safety of
any living organism cannot be guaranteed since the or-
ganism is subject to reproduction, further change,
growth, and adaptation. Therefore, some risk assessment
and the acceptance of minimal risks will be required if
newly altered organisms are to be developed. Some feel
that Rifkin's challenge will help to bring a thorough
review of the whole process of biotechnology regulation
and safety.
Finally, there is growing public concern for the treat-
ment and regulation of animals in research. Although it
seems axiomatic that researchers would humanely treat
the animals used in biomedical research, there have been
several highly publicized examples where laboratories
have been broken into, disagreeable pictures suggesting
animal mistreatment were taken, and in some cases, ani-
mals were 'liberated' (Fox 1984). Laws and regulations
are changing to reflect the public perception of scientists
and their work. However, tighter regulation and in-
creased paper work on laboratory animals add greatly to
the cost to the public of animal research. Another prob-
lem for researchers is that required reports made to the
institutional laboratory animal care and use committees
are disclosed as public information, which may jeop-
ardize or invalidate future university and corporate patent
applications. This, in turn, may negate the flow of dol-
lars from industry into mutually profitable research in
universities. Recently, bills have been proposed in Ohio
and elsewhere that would prohibit the use of pound ani-
mals in research. This would require the substitution of
animals bred specifically at greatly increased cost (Fox
1984). Since many pound animals would normally be
killed, it is not clear how the plan would benefit animals.
Concerned scientist groups such as the Scientist's Cen-
ter for Animal Welfare in the Washington, DC area are
beginning to take a more active role in regulating their
own use of animals. There is a movement afoot to elimi-
nate painful and unnecessary tests (e.g., the Draize test,
where toxic substances are placed in rabbits' eyes), and to
substitute the use of cell culture or test-tube types of
analyses for animal work wherever possible. Such reform
is long overdue.
The use of the animal model will probably continue to
be an important proving ground for biomedical and bio-
technological research. The American Society for Micro-
biology (ASM) in a recent position statement (Wodzinsky
1986) has said, "ASM believes that the use of animals in
research is necessary if progress is going to be made in
improving the quality of life and longevity of humans
and animals."
TECHNOLOGY DEVELOPMENT:
INTERACTION BETWEEN PRIVATE AND
PUBLIC SECTORS
A traditional academic paradigm (anecdotal) states
that industry profits from technology by focusing on
development, marketing, patent protection, and trade
secrets, whereas universities do mostly basic research and
report the results publicly. The result has been a lack of
knowledge in the area known as 'generic applied re-
search', linking basic science to applied research. These
bridging technologies have been considered a focus of
cooperation between industry and academe (N. Newell;
see NIH 1985).
Based on a recent study (Blumenthal et al. 1986), it is
estimated that there may be over 350 companies in the
United States practicing some form of biotechnology.
These firms contribute about $ 120 million to bio-
technology research projects and universities. On the
average, this type of research yields the company four
times as many patents per dollar as corporate, in-house
research. Altogether, these companies spend close to
$3 billion per year on biotechnology development
(Fig. 1). The amount spent on university research by the
private sector represents 16% of the total biotechnology
research budget in the universities. It relieves some com-
panies of the need to acquire certain unobtainable assets
such as access to a biomedical library or specialized labo-
ratory resources that may not be needed permanently.
There are also caveats and dangers in these associations
that must be surmounted. It is often heard that univer-
sities must protect freedom of information and the
'universality' of knowledge. Corporate patent policy can
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infringe upon this responsibility. Recently, Varrin and
Kukich (1985) formulated a useful set of guidelines that
can be used to develop consortia agreements between
academe and industry. These are designed to protect the
interests of both parties without compromising patent-
ability, graduate students' rights, or the obligation of
universities to publish their results. An example of a
viable consortial agreement (Olson 1986) is the contract
between the Monsanto Company and Washington Uni-
versity School of Medicine. Such contracts preserve in-
vestigator initiative, student participation, and timely
publication of results.
OTHER ETHICAL ISSUES
Many of the ethical issues facing the new industry
have already been addressed to some extent through the
last 13 years of experience with recombinant DNA.
Issues that have recently emerged include questions of
human gene engineering and permanent alteration of the
germ line.
Presently, human gene engineering is in the planning
stages. Serious proposals for somatic cell gene therapy are
being considered for comment at NIH. These involve
treatment of the cells of an individual in order to insert
a key gene that is defective or missing in the afflicted
individual. A major candidate for gene therapy is the
gene defect responsible for Lesch-Nyhan syndrome. The
critical factor in somatic cell gene therapy is that only
certain cells of the individual are being treated. The
method of choice is to insert the "repaired" gene into a
defective virus that delivers it stably into the chromo-
somes of the target cells of the afflicted individual. The
technique works in mice (Williams et al. 1984); several
groups plan to try it in humans during the next few years.
There is relatively little controversy regarding the science
since it does not involve permanent alteration of the
individual's germ cells (i.e., it cannot be passed on to
offspring). The major technical achievement is to devise
adequate "suicide" vectors or gene delivery systems that
will have sufficient biological containment built in to
insure safety and prevent reinfection.
The larger issue of permanent alteration of the human
germ line remains unsolved. The techniques for germ
line alteration already exist and have been used success-
fully in a number of animal species. There is no doubt
that agriculture will be permanently affected by this
technology. Virtually all scientists agree, however, that it
is still too early to attempt the germ line experiments on
humans. If and when such experiments are approved, it
will be after much public comment and debate and after
ample consideration by NIH and by RAC.
In nature, alterations of the germ line are rather fre-
quent. In most species examined, including Homo sapiens,
there are many examples of the existence of viral inser-
tions (retrotransposons) caused by agents similar to those
used by molecular biologists as gene insertion tools (for
a review, see Rogers 1984 or Baltimore 1985). Events as-
sociated with viral insertion probably resulted in the
300,000 or so Alu repeats found in human chromosomes.
Thus, viral infections are a major natural shaping force of
the genome. Some of the viruses are xenotropic; that is,
they are able to transport genes from one species to an-
other. Since the genetic code is universal, the transported
genes may be well-adapted to the new host when they
move in. Living organisms are the products of natural
genetic mobility. Gene sequences reveal many examples
of natural editing and splicing. This ability to efficiently
move genetic material in nature may provide important
clues toward understanding rapid evolutionary shifts that
have occurred at certain times (Erwin and Valentine
1984). Nevertheless, the use of such natural gene vectors
to permanently alter the human germ line must await
considerable animal experimentation and scrutiny. The
mere availability of the technology does not herald the
advisability of such experiments.
NEW TECHNOLOGY PATENTS
In 1980, a U.S. Supreme Court decision, Diamond vs.
Chakrabarty, made possible the patenting of genetically
engineered microorganisms. That same year, the Cohen-
Boyer patent on the process for the construction of re-
combinant DNA molecules was issued (for a review, see
Olson 1986). Patents provide 17 years of protection for
inventions that meet three criteria: they must be un-
obvious, original, and useful. As the technology has ad-
vanced, many patent issues have emerged. Does the
Chakrabarty decision apply to patents on higher or-
ganisms as well? Which parties hold rights when living
cell lines or organisms are patented? For instance, does
the donor of a useful cell line retain a proprietary interest?
Who is liable for living organisms or their progeny?
The patenting of new technology is also an issue that
involves our universities. Some university patents have
been extremely profitable and university patent policies
are presently leaning toward sharing royalty with faculty
inventors. This incentive may allow the recruitment of
excellent staff that the universities could not otherwise
afford, as well as provide incentive to generate profitable
new technology. In order to obtain an international
patent, the inventors must not have publicly disclosed
proprietary knowledge of the invention prior to the
patent application. Hence, there can be a delay of several
months between an invention and the time that it can be
published. This delay is normally not a problem unless it
prevents a student from graduating on time. Efforts
should be made not to involve students in proprietary
research if involvement will slow their progress. There
is also the question of whether universities should use
taxpayer dollars to develop patents that will involve
restricted use of inventions. This issue becomes in-
creasingly difficult as more and more faculty start new
corporations that may benefit from the technology. There
is a general opinion that the use of university facilities for
personal corporate activities constitutes a conflict of in-
terest (Varrin and Kukich 1985). Faculty members
should disclose their corporate interests and keep them
clearly separate from their academic jobs. To do otherwise
would allow faculty interests to be compromised.
The issue of what life forms are patentable remains
largely unresolved. Again, the biotechnological edu-
cation of lawyers, judges, and patent officials will be
tested as we enter this new legal arena.
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